^
    Back
    Association details:
    Biomarker:FGF3 amplification
    Cancer:Breast Cancer
    Drug:dovitinib (TKI258) (FGFR inhibitor, VEGFR inhibitor, PDGFR inhibitor, pan-TRK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Clin Cancer Res
    Title:

    Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer

    Excerpt:
    Four patients had FGF3 amplification as measured by qPCR, with tumor reductions of 100%, 30.8%, 23.0%, and 7.5%, respectively.
    DOI:
    10.1158/1078-0432.CCR-13-0190
    Trial ID:
    NCT00958971